Article Details
Retrieved on: 2023-11-16 21:12:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here